IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. (IPXL.PK)

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on management's current expectations and are subject to a number of known and unknown risks and uncertainties that could cause IMPAX's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, possible adverse effects resulting from the delisting of and suspension of trading in IMPAX's stock, the SEC proceeding to determine whether to suspend or revoke the registration of IMPAX's securities under section 12 of the Securities Exchange Act, IMPAX's delay in filing its periodic reports subsequent to its Form 10-Q for the third quarter of 2004, the time that will be required to complete the filing of IMPAX's delinquent periodic reports, IMPAX's ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX's ability to successfully develop and commercialize pharmaceutical products, IMPAX's reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in IMPAX's filings with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and IMPAX undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Note: All product sales data included herein are derived from data published by Wolters Kluwer Health for the 12 months ending September 30, 2007, except for the veterinary product Carprofen, which are derived from data published by Market Dynamics for the 12 months ending December 31, 2004.

Company Overview

- Technology based specialty pharmaceutical company
- Applying oral drug delivery technology and formulation expertise to the development of generic and branded pharmaceutical products
- Experienced senior management team
- Strong product portfolio
- Brand strategy offers potential long-term growth opportunities

Product Portfolio

- Approximately 118 generic products approved, pending or under development - targeting over $30 billion in US product sales
  - 41 Approved applications
  - 21 Applications pending at FDA
    - 5 ANDAs with Tentative Approval
  - Approximately 56 more under development
    - Additional products and/or strengths
- Additionally, 1 NDA for a brand product is pending and three additional brand products are under development

R&D Highlights

- 2007 - Received 5 approvals from FDA
  - Final Approval for generic versions of:
    - Corzide 40/5mg, 80/5mg
    - Ditropan XL 5,10mg
    - Xanax XR 0.5,1,2,3mg
    - Lopid 600mg
    - Persantine Tabs 25,50,75mg

Commercial Highlights

- 2007 – Launched 4 new products
  - Includes generic versions of:
    - Colestid Tablets 1g
    - Urecholine 5,10,25,50mg
    - Ditropan XL 5,10mg
    - Corzide 40/5mg, 80/5mg

Drug Delivery Capabilities

- Multiple delivery vehicles
- Applying new and existing drug delivery technologies to create new product opportunities
  (21 approved ANDAs utilize our drug delivery technologies)
- Developing and patenting new concepts and oral controlled release technologies
- Approximately 130 employees in our R&D effort

Development Strategy

- **Target limited competition environment**
  - Generic
    - Controlled Release – large, rapidly growing market
    - Specialty – technically challenging projects, barriers to entry, or other selected market opportunities
  - Brand
    - Targeting drugs used in treating CNS disorders
    - Focusing on improved versions of marketed compounds
      - Lower cost – much smaller R&D investment compared to NCEs
      - Lower risk of development – compounds previously shown to be safe and effective

Development Strategy

- Outsourced Development
  - Selected Generic Projects
    - 21 development projects outsourced
    - Utilizing 6 off-shore companies
    - Out of the 21 projects, 5 have been submitted, 2 have been approved
  - Provides
    - Lower cost of development
    - Increased development capacity

Expansion in Manufacturing Capacity

- 2007 initiative to establish FDA approved manufacturing plant in Taiwan
- Targets:
  - Fully operational in early 2010
  - Low cost structure
  - Well trained labor pool
  - When fully developed, approximately 50% increase in capacity

Generic Projects

Generic Projects

Current Status

Group	Specialty		Controlled Release		Total	
Category	Qty	Market*	Qty	Market*	Qty	Market*
Pending at FDA	10	$758	11	$7,118	21	$7,876
Under Development	17	$3,648	39	$16,020	56	$19,668
Total	**27**	**$4,406**	**50**	**$23,138**	**77**	**$27,544**

*US Market size, millions of US$

Generic Projects

Paragraph IV Filing Summary (24 total)

IMPAX Project	Generic of*	Est. Filing Order**	Initial Filing
Omeprazole 10,20,40mg DR	Prilosec (AZN)	5th of 10 total	4Q99
Bupropion 100,150mg ER	Wellbutrin SR (GSK)	3rd of 5 total	2Q00
Bupropion 150mg ER	Zyban (GSK)	2nd of 4 total	2Q00
Fenofibrate 67,134,200mg	Lofibra (Gate/Teva)	2nd of 2 total	2Q00
Loratadine & PSE 10/240mg ER	Claritin-D 24 hr (SGP)	2nd of 3 total	3Q00
Loratadine 10mg ODT	Claritin Reditab (SGP)	3rd of 3 total	4Q00
Loratadine & PSE 5/120mg ER	Claritin-D 12 hr (SGP)	1st of 2 total	4Q00
Metformin 500mg ER	Glucophage XR (BMS)	2nd of 15 total	3Q01[1]
Fexofenadine & PSE 60/120mg ER	Allegra-D (AVE)	2nd of 5 total	4Q01
Oxycodone 80mg ER	OxyContin (PUR)	3rd of 6 total	4Q01
Oxycodone 10,20&40mg ER	OxyContin (PUR)	3rd of 6 total	2Q02
Fenofibrate 54,160mg	Tricor Tablet (ABT)	2nd of 4 total	3Q02

*Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data.
Note [1]:Paragraph IV cert. & notice filed 4Q02. Products in Teal are marketed. White background means TA/FA rec'd.

Generic Projects

Paragraph IV Filing Summary

IMPAX Project	Generic of*	Est. Filing Order**	Initial Filing
Methylphenidate 18,27,36&54mg ER	Concerta (Alza/JNJ)	1st of 2 total	4Q02[2]
Carbidopa/Levodopa ER	Sinemet CR (BMS)	2nd of 4 total	4Q02
Carprofen 25,75 &100mg (Vet)	Rimadyl (Pfizer)	1st	4Q02
Bupropion 200mg ER	Wellbutrin SR (GSK)	1st of 2 total	1Q03
Oxybutynin 5,10,15mg ER	Ditropan XL (Alza/JNJ)	2nd of 2 total[3]	2Q03
Amphetamine 5,10,15,20,25&30mg ER	Adderall XR (Shire)	2nd of 5 total	3Q03
Metformin 750mg ER	Glucophage XR (BMS)	5th of 10 total	4Q03
Bupropion 150&300mg ER	Wellbutrin XL (GSK)	3rd of 4 total	4Q04
Colestipol 1gm	Colestid Tablet (Pfizer)	1st	4Q04[2]
Venlafaxine 37.5,75&150mg ER	Effexor XR (Wyeth)	2nd of 6 total	4Q05
Undisclosed			4Q06
Divalproex 250,500mg ER	Depakote ER (ABT)	5th of 5 total	1Q07

*Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data.
Note [2]--Paragraph IV certification and notice filed 3Q05. Note [3]--First to file on 15 mg strength.

Generic Projects

Paragraph IV Litigation Status Summary (24 total filed)

Litigation Resolved or Not Sued (20 projects)	
Bupropion 100,150mg ER (W)	Methylphenidate 18,27,36&54mg ER
Bupropion 150mg ER (Z)	Carbidopa/Levodopa ER
Fenofibrate 67,134,200mg Caps	Carprofen 25,75,100mg
Loratadine & PSE 10/240mg ER 24hr	Bupropion 200mg ER
Loratadine 10mg ODT	Oxybutynin 5,10&15mg ER
Loratadine & PSE 5/120mg ER 12hr	SE Amphetamine 5,10,15,20,25&30mg ER
Metformin 500mg ER	Metformin 750mg ER
Fenofibrate 54 &160mg Tabs	Colestipol 1gm Tabs
Bupropion 150 & 300mg ER (XL)	Undisclosed
Oxycodone 80mg ER	Oxycodone 10, 20, 40 mg ER

Generic Projects

Paragraph IV Litigation Status Summary (24 total filed)

Project	Litigation Status
Omeprazole 10, 20 & 40mg DR	May 2007 trial court decision that Impax product infringes; patent not invalid. Notice of appeal filed.
Fexofenadine & PSE ER	No trial date scheduled.
Venlafaxine 37.5, 75, 150mg ER	Markman hearing held in June 2007; awaiting Court's decision. Trial expected 1Q08.
Divalproex 250,500mg ER	Discovery stage.

Commercial Strategy

Strategic Alliances for Generic Projects

- **Teva**
  - Signed June 2001
  - First product shipped 1Q 2004
  - 12 Rx products, 11 filed to date, 11 disclosed
- **Dava/Purdue**
  - Signed November 2005
  - First product shipped 4Q 2005
  - 1 Rx product, 4 Strengths, Oxycodone HCl ER Tablets; 10, 20, 40 & 80 mg
  - Signed patent settlement with Purdue Pharmaceuticals in March 2007 which granted IMPAX a full release and ability to sell a limited amount of product for a limited amount of time
  - Amended terms of Dava agreement that better reflects the changes in the marketplace (e.g. larger share of profits to IMPAX in exchange for relieving DAVA of all future appointment fees)

Brand Projects

Brand Projects

- Targeting improved versions of existing chemical entities
  - Reduced risk and expense associated with development as compared to NCE development.
  - Reduced time of development as compared to NCE development
- Utilize development and drug delivery expertise
  - Improve patient compliance and outcomes

Brand Projects

- Focus on Central Nervous System (CNS) drugs
  - Rapidly growing therapeutic area
  - Focus on CNS disease states, including movement disorders such as Parkinson's disease.
  - These movement disorders are frequently treated by the approximately 8,300 practicing neurologists, of which about 3,500 write the majority of prescriptions.
  - This group can be addressed by the small existing sales force by adding these products to the current effort for Carbatrol.

Brand Projects

- Despite being the standard for treating Parkinson's Disease, existing levodopa therapy does not meet certain needs:
  - Delayed or unpredictable "on"
  - Motor fluctuation and dyskinesias
  - Pill burden
  - True delivery of continuous dopaminergic stimulation

Brand Projects



- VADOVA™ (carbidopa-levodopa) is formulated with the goal of meeting one of these unmet needs by allowing a reduction in pill burden.

Brand Projects

- **VADOVA**
  - The effective date of acceptance of the VADOVA NDA by FDA was May 3, 2005.
  - "Non-approvable" letter received from FDA March 3, 2006.
  - An Amendment was filed on January 18, 2007 addressing the concerns raised in the Agency's non-approvable letter of March 2006.
  - Two posters were presented at the Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders in Istanbul, Turkey on June 7, 2007.
  - U.S. Patent No. 7,094,427 issued. Additional U.S. and foreign applications pending.
- **IPX056**
  - For our second brand project, IPX056, a clinical trial study is being conducted in individuals with established spasticity resulting from multiple sclerosis.

Commercial Strategy

Strategic Alliances for Branded Projects

- **Carbatrol ® (Shire)**
  - Signed January 2006
  - Promoted Product: Carbatrol® (carbamazepine extended release)
  - Payments of $40 million to be received over three years to provide promotional services
  - Target audience – Neurologists
  - Impax Pharmaceuticals Sales Force formed and detailing of Carbatrol launched – July 2006

Significant Milestones

Milestone	2000/ 2001	2002	2003	2004	2005	2006	2007 (YTD)
Applications Filed	**16**	**8**	**8**	**6**	**10**	**6**	**6**
• PPG IV filings	9	5	4	1	3*	1	1
• IND filings	0	0	2	1	0	0	0
• NDA filings	0	0	0	0	1	0	0
Approvals (Total)	**3**	**8**	**9**	**11**	**6**	**6**	**6**
• Tentative approval	0	5	2	2	1	1	1

*Includes amendments to two previously filed applications—not included in 2005 applications filed

Filing Goal 2007: 8-10 with focus on modified-release products

Financials

	Sep-06	Dec-06	Mar-07	Jun-07	Sep-07
		(in thousands and unaudited)			
Cash and Investments	27,353	29,092	46,648	62,125	141,041
Senior Debt	5,316	5,430	5,375	5,310	5,244
Convertible & Subordinated Debt	75,000	75,000	75,000	75,000	75,000
Subordinated Settlement Obligation	11,000	11,000	10,616	10,226	9,830
Total Senior and Subordinated Debt	91,316	91,430	90,991	90,536	90,074
Less Current Maturities	1,283	1,830	1,829	4,009	3,984
Long-Term Debt	90,033	89,600	89,161	86,527	86,090
Capital Expenditures	17,820 (9 Months)	20,793 (12 Months)	6,269 (3 Months)	11,247 (6 Months)	15,686 (9 Months)

Highlights

- Experienced management with strong industry knowledge and technical expertise
- Broad base of drug delivery technology, formulation and development expertise
- Strong product portfolio
- Branded product strategy offers potential additional long-term growth opportunities

Thank you for your interest in

IMPAX Laboratories, Inc.